| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From the Departments of Nutrition (FMS and NLG), Internal Medicine (ACV and KK), and Obstetrics and Gynecology (MJM), University of California, Davis, and the Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, The Permanente Medical Group (Kaiser Permanente), Sacramento, CA (MJM).
2 Supported in part by a grant from DuPont Protein Technologies, St Louis. 3 Reprints not available. Address correspondence to FM Steinberg, Department of Nutrition, University of California, Davis, One Shields Avenue, Davis, CA 95616. E-mail: fmsteinberg{at}ucdavis.edu.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Objective: The objective was to investigate whether the consumption of soy protein with isoflavones would result in improved vascular reactivity and decreased biochemical markers of endothelial dysfunction and inflammation, independent of enhanced lipid and antioxidant effects.
Design: Healthy postmenopausal women (n = 28) were enrolled in a randomized, double-blind, crossover study, and they consumed 25 g of 3 protein products/d for 6 wk each, with intervening washout periods. The products were isolated soy protein with isoflavones, ethanol-washed isolated soy protein with trace isoflavones, and total milk protein, which supplied 107, 2, and 0 mg total isoflavone (aglycone) units/d, respectively. We studied vascular function by using brachial artery reactivity values, plasma concentrations of vasoactive factors, endothelial inflammatory markers, and plasma isoflavone concentrations. The resistance of whole plasma and isolated LDL to copper-mediated oxidation was measured by conjugated diene formation.
Results: Postocclusion peak flow velocity of the brachial artery was significantly (P = 0.03) lower after treatment with isolated soy protein with isoflavones, which is consistent with a vasodilatory response, than after treatment with total milk protein. Plasma isoflavones and metabolites were significantly (P < 0.01) higher after treatment with isolated soy protein with isoflavones. There were no significant changes in biochemical cardiovascular disease risk markers or conjugated diene formation between the 3 dietary groups.
Conclusion: Daily consumption of soy protein with isoflavones can result in positive vascular effects that are independent of lipid and antioxidant effects in healthy postmenopausal women.
Key Words: Soy • isoflavone • cardiovascular disease • endothelial function • lipid oxidation • postmenopausal women
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Soy is a rich source of the polyphenolic isoflavones genistein and daidzein. Isoflavones are structurally similar to estradiol and have a high binding affinity for the primary estrogen receptor in the vascular wall, estrogen receptor ß, relative to that for estrogen receptor 
(7–9). Genistein, the predominate isoflavone, contributes to a decrease in the oxidative susceptibility of LDL in vitro and ex vivo (10–12) and has also been shown to have other cellular activities that may influence vascular tissue metabolism, such as inhibition of tyrosine kinase activity, decreased smooth muscle cell proliferation, and nitric oxide–dependent relaxation (13–15).
Animal data show that isoflavones improve vascular reactivity in a manner similar to that of estradiol and that they may interact with estradiol to enhance endothelial function (16–18). However, the effects of soy and isoflavones on vascular reactivity in menopausal women are less clear. Five studies investigated this question in postmenopausal women by using total isoflavones in a range of 54–118 mg/d (19–23). Two of these studies reported positive changes: one study found significant improvements in systemic arterial compliance (19), and the other, more recent study reported a significant increase in flow-mediated vasodilation of the brachial artery, which was associated with changes in biochemical measures of endothelial metabolites (20). Of the other 3 studies, 1 reported significantly decreased blood pressure with peripheral vasodilation (23), and 2 reported no significant changes in endothelial function (21, 22).
Further investigation into the effects of soy protein with isoflavones in postmenopausal women is warranted to clarify issues of efficacy with regard to vascular function. The aim of the present study was to obtain information as to the additional benefits that soy protein with and without isoflavones may bring to an already healthy diet, by determining whether soy improved endothelial function, CVD risk markers, and antioxidant defense in healthy, free-living postmenopausal women who maintained their usual diets and use of vitamin and mineral supplements. This question is particularly relevant, given the increasing promotion and use of soy products and supplements in this population segment and in light of the still unanswered questions about potential cardiovascular benefits.
|
SUBJECTS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Study design
Participants were assigned to 1 of 3 treatment schemes in a randomized, double-blind, crossover design, such that all subjects ultimately underwent all 3 treatment regimens. Each scheme outlined the order of consumption of the 3 protein supplements: isolated soy protein with naturally occurring isoflavones (Soy+), ethanol-washed isolated soy protein with trace amounts of isoflavones (Soy-), and total milk protein (TMP), which contained 107.67, 1.82, and 0 mg of total isoflavones (aglycone units), respectively, in a daily dose of 25 g protein. This allowed for comparison of the effects due to isoflavones themselves with those due to the protein matrix. The macronutrient, vitamin, and mineral contents of the 3 protein powders were equal. Details of the isoflavone and nutrient contents of the study products are shown in Table 1
. DuPont Protein Technologies (St Louis) supplied the protein products used in the study.
|
A 6-wk supply of the assigned protein was provided in measured individual packets at weeks 0, 6, and 16. Any unused packets of protein were returned by the participants, and the quantity returned provided a gross measurement of adherence to the intervention. The participants mixed the protein powder with their choice of beverage and consumed the full serving daily. Instructions were given on how to include the daily protein in their normal diet without increasing their usual protein or energy intake.
Participants were advised to maintain their usual dietary habits consistently throughout the study and were instructed to abstain from all additional soy foods, soy- or phytoestrogen-fortified products, and known phytoestrogen-rich herbal supplements. Each participant’s vitamin and mineral supplement use was recorded at the first clinic visit (week 0), and participants were instructed to make no changes in the doses used during the study period. They were advised to abstain from alcoholic beverages and phytochemical-rich foods (including, tea, flaxseed products, and chocolate), which may alter endothelial function, throughout the study and in particular for 24 h before each clinic visit.
Participants were instructed on how to keep accurate 3-d food records. Records were kept for 3 alternating days, including one weekend day, during the week before the clinic visit at weeks 6, 16, and 26. Completed food records were reviewed for adequate details and adherence to guidelines. Dietary intake was analyzed with the use of NUTRITIONIST V software, version 2 (First Data Bank, San Bruno, CA).
Brachial artery reactivity
Changes in vessel diameter after reactive hyperemia (endothelium-dependent vasodilation) and after the taking of sublingual nitroglycerin (endothelium-independent vasodilation) were measured according to previously described methods (24). Brachial artery ultrasound scans were performed after an overnight fast and with the subjects at rest after lying in the supine position for ≥ 10 min. Studies were performed by 2 experienced vascular ultrasound technicians with the use of a Sonos 5500 ultrasound machine (Hewlett-Packard, Palo Alto, CA) and a high-resolution (7.5-MHz) linear array transducer. The variability in measurements between the tests performed by the 2 technicians was < 5%.
The left brachial artery was imaged above (3–7 cm) the antecubital fossa and arterial bifurcation with a vascular probe positioned at an angle of 60°. First, baseline brachial artery diameter and flow were measured. Then, a blood pressure cuff was inflated to suprasystolic pressure (≥ 30 mm Hg higher than the subject’s systolic blood pressure), and the vessel was compressed for 5 min. To obtain the postocclusion data, the cuff was deflated and brachial artery diameter and flow were remeasured within 15 s after compression during reactive hyperemia. A second baseline measurement of brachial artery diameter and flow was taken after 10 min. Then, a sublingual nitroglycerin tablet (0.4 mg) was administered to each subject, and a postnitroglycerin measurement of left brachial artery flow velocity and diameter was made within 4 min. The mean of the 2 baseline measurements was defined as the resting vessel diameter. Peak flow velocity (PFV) was defined as blood flow in cm/s during reactive hyperemia. The change in PFV was calculated as the percentage of change in flow velocity after occlusion compared with the mean of the 2 baseline values. Flow-mediated dilation was calculated as the percentage of change in vessel diameter after occlusion compared with the mean of the 2 baseline values. In addition, the percentage of change in postnitroglycerin vessel diameter and flow was calculated and compared with the baseline and postocclusion values to evaluate the endothelium-dependent dilation in relation to the maximum dilation of the brachial artery as assessed after nitroglycerin administration.
Biochemical endothelial cell markers
To determine whether changes in brachial artery reactivity were coupled with changes in biochemical markers of endothelial function and vascular inflammation, we measured plasma concentrations of vasoactive factors and inflammatory markers. The counterregulatory vasoactive factor endothelin 1 (ET-1) and nitric oxide metabolites were of particular interest because of genistein’s postulated nitric oxide–dependent effects on the vascular wall. Plasma total nitrite concentration was assayed with a colorimetric kit (Cayman Chemical, Ann Arbor, MI), which uses the reduction of nitrates to nitrites and the addition of Griess reagents (Cayman Chemical) for detection at 550 nm. Citrated plasma was ultrafiltrated through a 30-kDa molecular weight microfuge ultrafiltration device (Millipore, Bedford, MA) before assay to reduce background absorbance. Sensitivity of the assay was 2.5 mmol/L. Serum ET-1 was measured with the use of a QuantiGlo chemiluminescence immunoassay (R & D Systems, Minneapolis). The sensitivity of the assay was 0.16 pg/mL. Crossreactivity with endothelium 3 was 7.8%, that with endothelium 2 was 27.4%, and that with proendothelin was negligible.
Cellular adhesion molecules (CAMs) are among the many markers of vascular inflammation and are known to respond to hormonal manipulation. We sought to determine the effect of the soy diets on 2 such markers, soluble intercellular CAM-1 (sICAM-1) and soluble vascular CAM-1 (sVCAM-1), and on E-selectin. Soluble CAMs were measured in serum with the use of sandwich enzyme-linked immunoassay kits (R & D Systems). Serum samples were diluted 20-fold for measurement of sICAM-1 and E-selectin and 50-fold for measurement of sVCAM-1. The sensitivity of the assays was 0.35, 0.1, and 2.0 ng/mL, respectively, and there was no cross-reactivity with other adhesion molecules. Interassay and intraassay CVs for all assays were < 10% as determined in human serum.
Follicle-stimulating hormone and estradiol
Menopausal status was verified by serum concentrations of follicle-stimulating hormone measured at the University of California, Davis, Medical Center clinical laboratory with the use of a two-site chemiluminometric immunoassay (Bayer Diagnostics, Medfield, MA). Plasma estradiol (E-2) and estrone (E-1) concentrations were measured at the Laboratory for Reproductive Biology, University of North Carolina, Chapel Hill, with the use of radioimmunoassay kits (Diagnostic Systems Laboratories, Inc, Webster, TX). The intraassay and interassay CVs for analysis of E-1 were 9.4% and 10.2%, and those for analysis of E-2 were 5.3% and 4.9%, respectively. The E-1 radioimmunoassay has cross-reactivity with E-2 of 1.25% and the E-2 radioimmunoassay has cross-reactivity with E-1 of 0.86%. The cross-reactivity of both the E-1 and E-2 radioimmunoassays with isoflavones is unknown, although it is < 1% with all other mammalian estrogens, except as noted above. The estrone and estradiol kits were sensitive at concentrations of 4.4 and 23.9 pmol/L, respectively.
Plasma isoflavones
Plasma concentrations of the isoflavones and metabolites genistein, daidzein, dihydrodaidzein, equol, ortho-desmethylangolensin, and glycitein were measured by using HPLC with electrochemical detection (25). Briefly, samples were hydrolyzed overnight in the presence of ß-glucuronidase in a sodium acetate buffer. Isoflavones were then extracted into methyl tert-butyl ether, dehydrated, and reconstituted in methanol and water. Separation was performed with the use of reverse-phase HPLC with a Model 5600 CoulArray 8 Channel Detector (ESA, Inc, Chelmsford, MA) and quantified with the use of standards of known concentration. The minimum concentration for detection for all isoflavones was 5 ng/mL. The intraassay and interassay CVs for all 6 isoflavones ranged from 3% to 15%.
Blood lipids
Fasting serum lipids (total and HDL cholesterol and triacylglycerol) were measured with the use of automated enzymatic methods at the clinical laboratory. Analysis was performed on a Synchron LX-20 System (Beckman Coulter, Inc, Brea, CA). LDL cholesterol was calculated by using the equation of Friedwald et al (26). All samples were processed within 2 h of collection.
Formation of conjugated dienes in whole plasma and LDL oxidation
To determine whether soy protein with isoflavones functioned as a lipid antioxidant in normolipidemic subjects, we determined the resistance of whole plasma and isolated LDL to copper-mediated oxidation. The formation of conjugated dienes (CDs) resulting from the oxidation of polyunsaturated fatty acids in whole plasma exposed to copper ions was measured with the use of a spectrophotometric method adapted from Kontush et al (27). Citrated plasma samples were diluted 1:50 with phosphate-buffered solution (pH 7.4), and 10 µL of a 10-nmol CuSO4/L solution was added to the diluted plasma, for a final copper concentration of 100 µmol/L. Absorption was measured at 245 nm with a 12-cell visible spectrophotometer (UV-1601; Shimadzu Scientific Instruments, Inc, Columbia, MD) with an external temperature controller set at 37 °C. Absorption was read until a maximum CD formation was reached and a plateau was observed (
120 min). Data were graphed as time (min) versus absorbance. The length of time before CD formation began (lag time) was calculated by the intersection of the lines corresponding to the lag phase and the propagation phase on the graph. Samples from each of the 4 study time points for each participant were analyzed in triplicate in the same run to minimize variability.
LDL was isolated from plasma by microultracentrifugation according to the method of Brousseau et al (28). EDTA was removed from the LDL by overnight dialysis in phosphate-buffered solution (pH 7.4) treated with Chelex 100 (Bio-Rad, Richmond, CA) and purged with nitrogen. The amount of cholesterol in the samples was quantified with the use of a Boehringer Mannheim cholesterol kit (Boehringer Mannheim, Indianapolis). CD formation was measured as described by Esterbauer (29). A volume of dialyzed LDL sample containing 75 µg of cholesterol was added to a quartz cuvette containing phosphate-buffered solution (pH 7.4) and copper sulfate to yield a final concentration of 5 µmol/L in 1 mL total volume. Absorption was read at 234 nm until maximum CD formation was reached and a plateau was observed (200 min). Data were analyzed in the same manner as described above in the whole-plasma oxidation studies. All samples for each participant were analyzed in duplicate in the same run.
Statistical analysis
Data are presented as means (± SEMs), unless stated otherwise, of duplicate or triplicate sample values. Statistical analysis was performed with the use of SPSS for WINDOWS software, version 10.0 (SPSS Inc, Chicago) and SAS for WINDOWS software (SAS Institute, Inc, Cary, NC). Comparisons among the 3 treatments were done by repeated-measures analysis of variance and two-factor repeated-measures analysis of variance with interaction terms for comparison of brachial artery reactivity with and without nitroglycerin. The Tukey-Kramer post hoc test for multiple comparisons was used. Differences were considered significant if P ≤ 0.05.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The baseline characteristics of the 28 women completing the study (Table 2) were comparable among treatment groups with regard to age, body mass index, follicle-stimulating hormone, and blood lipids. Body weight did not change significantly in any of the treatment groups throughout the 26-wk study. Serum estrone and estradiol concentrations were consistent with a lack of endogenous ovarian estrogen production in all of the women and did not vary after any of the treatments (observations not shown). No effect of treatment order was seen for any of the variables examined.
|
).
|
525% and 450% above the recommended daily allowances for this population. Vitamin supplement users were included in the study to evaluate the potential for soy protein to modulate the oxidative susceptibility of whole plasma and LDL under these conditions, because of the widespread use of supplements in this age group. Subgroup analysis of nonsupplement users did not reveal any trends in analyses compared with vitamin supplement users, but the number of subjects was not large enough for the detection of significance. The consumption of meatless meals, fruit, and vegetables was also common in this study population. During the entire study period, < 45% of the meals eaten by 13 of the participants were meatless. The number of servings of lean and high-fat meats/d for all participants, calculated with the use of NUTRITIONIST V software, was 4.06 ± 1.67 and 0.45 ± 0.71, respectively. The number of servings of fruit and vegetables/d for all participants was 3.07 ± 1.98 and 1.55 ± 1.67, respectively. Adherence to the daily protein supplements was ≥ 93% throughout the study.
Plasma isoflavones
The plasma concentrations of isoflavones and metabolites were 5 pg/dL or less in the Soy– and TMP groups. Fasting mean plasma concentrations of daidzein, dihydrodaidzein, equol, genistein, and ortho-desmethylangolensin at completion of the Soy+ treatment were 55.2 ± 1.8, 21.3 ± 7.7, 35.6 ± 10.3, 81.9 ± 14.4, and 30.5 ± 6.5 pg/dL, respectively, and they were significantly (P ≤ 0.01) higher than values in samples taken at baseline and after the Soy- and TMP treatments (observations not shown). The daidzein concentration in the TMP group was initially not significantly lower, because 2 participants presented with daidzein values at baseline that were comparable to their concentration after the Soy+ treatment, probably as a result of inadvertent dietary indiscretion. An analysis of the data that excluded these 2 participants resulted in a daidzein value after the TMP treatment that was significantly lower than that after the Soy+ treatment. All other data were analyzed with the exclusion of these 2 participants, and no effects on statistical significance were found. Equol was produced by 10 of the subjects. Baseline characteristics of these subjects were similar to those of the rest of the experimental group. Subgroup analysis of the data including only the equol producers did not result in variations from the analysis of all 28 participants, but the number of subjects was not large enough to detect significance (data not shown).
Brachial artery reactivity
To assess the effect of the soy protein diets on vascular function, as measured by brachial artery reactivity, we compared the baseline, postocclusion, and postnitroglycerin brachial artery vessel diameter and PFV in the Soy+, Soy-, and TMP (control) treatment groups. The brachial artery postocclusion vessel diameters did not differ significantly among treatment groups and were within 5% of the baseline values. Postnitroglycerin vessel diameters increased 16–18% compared with baseline, and they also did not differ among groups. However, the PFV was significantly (P = 0.03) lower at the end of the Soy+ treatment than that at the end of the TMP treatment, which is consistent with a vasodilatory response (Figure 1). The Soy- treatment PFV did not differ significantly from the TMP or Soy+ treatment PFV. There was no significant (P = 0.31) effect for the nitroglycerin-by-treatment interaction term in the two-factor repeated-measures analysis of variance. Thus, the overall effect of the Soy+ treatment was consistent between conditions (ie, with and without nitroglycerin), although the average values with nitroglycerin tended to be lower.
|
. Plasma nitric oxide–derived products (ie, total nitrate + nitrite concentration) did not differ significantly among treatment groups or when compared with the mean baseline value. Similarly, ET-1 concentrations did not differ significantly among groups or when compared with the mean baseline. There was a trend for nitric oxide to increase and for ET-1 to decrease in the Soy+ group compared with the other diet treatments, but this trend did not reach statistical significance. No significant differences were observed in the serum concentrations of sVCAM-1 and sICAM-1 or in soluble E-selectin among the treatment groups.
|
). However, in comparison to baseline, there were decreases in total and LDL cholesterol in the Soy+ group [0.09 and 0.03 mmol/L (or 3.59 and 1.12 mg/dL), respectively], unchanged lipid values in the Soy- group [0.01 and -0.02 mmol/L (or 0.22 and -0.64 mg/dL), respectively], and increases in lipid values in the TMP group [0.08 and 0.04 mmol/L (or 3.25 and 1.73 mg/dL), respectively]. The latter changes were similar in magnitude but opposite in direction to the changes seen in the Soy+ group. Measurement of lipid oxidation susceptibility by CD formation in whole plasma and isolated LDL showed no significant differences among treatment groups either as absolute values or as the change in lag time from baseline (data not shown).
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
We observed that PFV with the Soy+ treatment was significantly lower than that with the TMP treatment. These findings are consistent with the research of others and suggest that, although both the isoflavone and protein components of soybeans can have a beneficial effect on cardiovascular health, the combination of soy protein and isoflavones probably conveys more benefit than does either component alone (38, 39). The endothelium-independent response to nitroglycerin was robust in all subjects, which indicated normal physiologic responsiveness and supported the possibility of an endothelium-dependent mechanism for the reductions observed in PFV with the consumption of soy protein with isoflavones. It was surprising that an increased vessel diameter was not detected, despite the decrease in flow velocity. However, it is possible that the amount of endothelium-dependent vasodilation was maintained to a greater extent in this healthy population than in other studies of postmenopausal women. Factors possibly contributing to the variable results in this field that have been observed in previous studies include the length of time the soy or isoflavone supplement is consumed, the dose of isoflavones, the presence of CVD risk factors such as hypercholesterolemia that impair endothelial function, and the sensitivity of the values of endothelial responsiveness that are assessed (19–23, 40).
Only one prior study examined endothelial function in postmenopausal women in response to soy protein with isoflavones (containing 54 mg genistein/d), and it did not find a response in brachial artery reactivity but, interestingly, did find significant decreases in the pulse wave velocity of the femorodorsalis arterial segment and in blood pressure, results that are consistent with peripheral vasodilation (23). In a recent study of postmenopausal women receiving isoflavone tablets for 6 mo, investigators found significantly increased flow-mediated brachial artery vasodilation that was correlated with an increased ratio of nitric oxide products to ET-1, which suggested possible pathways through which isoflavones may mediate vascular reactivity (20). Another research group found significant improvements in systemic arterial compliance (19). Both of these studies used tablets that delivered 45–54 mg genistein/d, a dose essentially similar to the 55 mg genistein contained in the daily soy protein in the current study. The remaining studies used soy isoflavone tablets containing 40 mg or unspecified amounts of genistein, taken daily for periods of 2–9 wk, and did not show improvements in brachial artery reactivity (21, 22). Some of these studies have included perimenopausal and postmenopausal women who had mild endothelial dysfunction or hypertension, but these populations were healthy for the most part. Thus, in the context of prior studies, our data support a positive effect on vascular function of the consumption of soy protein with isoflavones containing 50 mg genistein/d, even in a very healthy, normolipidemic postmenopausal population.
There were no previous reports in the clinical literature of the effect of soy isoflavones on the soluble plasma CAMs VCAM-1, ICAM-1, and E-selectin. The CAMs are elevated in persons with coronary artery disease or diabetes and in postmenopausal women, and they also are markers for endothelial dysfunction, inflammation, and CVD risk (41–43). Estrogen replacement therapy results in fewer soluble adhesion markers (44, 45). Our results reveal no significant changes in soluble CAMs with the consumption of soy with or without isoflavones, which suggests no benefit to these risk markers in a healthy postmenopausal population without evidence of inflammation. Thus, the improved vasoreactivity in response to the Soy+ treatment does not appear occur via an inflammation-sensitive mechanism. It is possible, however, that biochemical markers of endothelial function and of endothelial reactivity may be more responsive to soy isoflavones when other CVD risk factors and inflammation are present; this would be analogous to the greater lipid-lowering effects of soy protein with isoflavones that are seen in hypercholesterolemic persons.
Studies examining the effects of soy proteins with isoflavones in postmenopausal women showed modest blood lipid–lowering effects relative to HRT, with responses being more robust in persons with significant hyperlipidemia (39, 46–51) and inconsistent in normolipidemic persons (23, 52). The small changes in plasma lipids in response to soy proteins did not reach statistical significance in our healthy, normocholesterolemic population, which is consistent with previous results. The subjects in the current study had self-selected diets that met the National Cholesterol Education Program Step II guidelines and often included a large proportion of meatless meals. Two previous studies noted a lack of plasma lipid response to soy proteins when the intake of cholesterol is low (≤ 200 mg/d) (53, 54). In contrast, purified isoflavones, which are essentially devoid of protein, do not lower lipids or decrease oxidation susceptibility, which suggests a role for the soy protein matrix (21, 22, 55).
Most of the studies that measured oxidation resistance in response to soy treatment showed improvements in either the lag time for CD formation (11, 12) or the in vivo CD formation with control for antioxidant intake (56). We did not find significant improvements in the antioxidant capacity of whole plasma or isolated LDL cholesterol. As predicted, the regular high intake of fruit and vegetables in addition to the use of vitamin and mineral supplements in this free-living population provided sufficient antioxidants, which masked any antioxidant effects of the soy protein. This finding does not preclude the possibility that a beneficial effect could be observed in women with suboptimal diets that are low in antioxidant-containing fruit and vegetables, as would be consistent with previous reports.
In summary, in this study we showed that a diet rich in soy protein with isoflavones resulted in significantly increased plasma isoflavone concentrations and significant favorable effects in brachial artery PFV that are consistent with a vasodilatory response. Our results are significant because heretofore it was unclear whether soy has vascular benefits in a healthy, normolipidemic, menopausal population. The data suggest that the consumption of 25 g soy protein with 55 mg genistein in a total consumption of 107 mg isoflavones/d has a benefit for vascular reactivity that is independent of plasma antioxidant actions and lipid-lowering effects. Our findings have implications for the growing population of healthy postmenopausal women who may wish to consume soy products with isoflavones or naturally occurring selective estrogen-receptor modulators. Further research is needed to clarify both the mechanisms by which soy proteins and isoflavones affect vascular tissues, and the clinical significance of such effects.
|
ACKNOWLEDGMENTS |
|---|
FMS, MJM, ACV, and NLG contributed to the design of the study, collection and analysis of the data, and manuscript preparation; FMS, MJM, NLG, and KK collected the data. None of the authors had any financial or personal interest in any company or organization sponsoring the research.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  T. A. Barringer, L. Hatcher, and H. C. Sasser Potential Benefits on Impairment of Endothelial Function after a High-fat Meal of 4 weeks of Flavonoid Supplementation Evid. Based Complement. Altern. Med., July 3, 2008; (2008) nen048v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Gardner, M. Messina, A. Kiazand, J. L. Morris, and A. A. Franke Effect of Two Types of Soy Milk and Dairy Milk on Plasma Lipids in Hypercholesterolemic Adults: A Randomized Trial J. Am. Coll. Nutr., December 1, 2007; 26(6): 669 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fuchs, K. Vafeiadou, W. L Hall, H. Daniel, C. M Williams, J. H Schroot, and U. Wenzel Proteomic biomarkers of peripheral blood mononuclear cells obtained from postmenopausal women undergoing an intervention with soy isoflavones Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1369 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Clerici, K. D. R. Setchell, P. M. Battezzati, M. Pirro, V. Giuliano, S. Asciutti, D. Castellani, E. Nardi, G. Sabatino, S. Orlandi, et al. Pasta Naturally Enriched with Isoflavone Aglycons from Soy Germ Reduces Serum Lipids and Improves Markers of Cardiovascular Risk J. Nutr., October 1, 2007; 137(10): 2270 - 2278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R Matthan, S. M Jalbert, L. M Ausman, J. T Kuvin, R. H Karas, and A. H Lichtenstein Effect of soy protein from differently processed products on cardiovascular disease risk factors and vascular endothelial function in hypercholesterolemic subjects Am. J. Clinical Nutrition, April 1, 2007; 85(4): 960 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Taku, K. Umegaki, Y. Sato, Y. Taki, K. Endoh, and S. Watanabe Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials Am. J. Clinical Nutrition, April 1, 2007; 85(4): 1148 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Azadbakht, M. Kimiagar, Y. Mehrabi, A. Esmaillzadeh, F. B. Hu, and W. C. Willett Soy Consumption, Markers of Inflammation, and Endothelial Function: A cross-over study in postmenopausal women with the metabolic syndrome Diabetes Care, April 1, 2007; 30(4): 967 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Erdman Jr., D. Balentine, L. Arab, G. Beecher, J. T. Dwyer, J. Folts, J. Harnly, P. Hollman, C. L. Keen, G. Mazza, et al. Flavonoids and Heart Health: Proceedings of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, Washington, DC J. Nutr., March 1, 2007; 137(3): 718S - 737S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Shimozawa, K. Okajima, and N. Harada Estrogen and isoflavone attenuate stress-induced gastric mucosal injury by inhibiting decreases in gastric tissue levels of CGRP in ovariectomized rats Am J Physiol Gastrointest Liver Physiol, February 1, 2007; 292(2): G615 - G619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cupisti, L. Ghiadoni, C. D'Alessandro, I. Kardasz, E. Morelli, V. Panichi, D. Locati, S. Morandi, A. Saba, G. Barsotti, et al. Soy protein diet improves endothelial dysfunction in renal transplant patients Nephrol. Dial. Transplant., January 1, 2007; 22(1): 229 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Cortes, I. Nunez, M. Cofan, R. Gilabert, A. Perez-Heras, E. Casals, R. Deulofeu, and E. Ros Acute Effects of High-Fat Meals Enriched With Walnuts or Olive Oil on Postprandial Endothelial Function J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1666 - 1671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Peluso Flavonoids Attenuate Cardiovascular Disease, Inhibit Phosphodiesterase, and Modulate Lipid Homeostasis in Adipose Tissue and Liver Experimental Biology and Medicine, September 1, 2006; 231(8): 1287 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Sacks, A. Lichtenstein, L. Van Horn, W. Harris, P. Kris-Etherton, M. Winston, and for the AHA Nutrition Committee Soy protein, isoflavones, and cardiovascular health: a summary of a statement for professionals from the american heart association nutrition committee. Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1689 - 1692. [Full Text] [PDF]
|
|
|
|
|
|
T. A Ryan-Borchers, J. S. Park, B. P Chew, M. K McGuire, L. R Fournier, and K. A Beerman Soy isoflavones modulate immune function in healthy postmenopausal women Am. J. Clinical Nutrition, May 1, 2006; 83(5): 1118 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Sacks, A. Lichtenstein, L. Van Horn, W. Harris, P. Kris-Etherton, M. Winston, and for the American Heart Association Nutrition Commi Soy Protein, Isoflavones, and Cardiovascular Health: An American Heart Association Science Advisory for Professionals From the Nutrition Committee Circulation, February 21, 2006; 113(7): 1034 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L Hall, K. Vafeiadou, J. Hallund, S. Bugel, C. Koebnick, M. Reimann, M. Ferrari, F. Branca, D. Talbot, T. Dadd, et al. Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: interactions with genotype and equol production Am. J. Clinical Nutrition, December 1, 2005; 82(6): 1260 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Adams, D. L. Golden, J. K. Williams, A. A. Franke, T. C. Register, and J. R. Kaplan Soy Protein Containing Isoflavones Reduces the Size of Atherosclerotic Plaques without Affecting Coronary Artery Reactivity in Adult Male Monkeys J. Nutr., December 1, 2005; 135(12): 2852 - 2856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Atkinson, C. L. Frankenfeld, and J. W. Lampe Gut Bacterial Metabolism of the Soy Isoflavone Daidzein: Exploring the Relevance to Human Health Experimental Biology and Medicine, March 1, 2005; 230(3): 155 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Register, J. A. Cann, J. R. Kaplan, J. K. Williams, M. R. Adams, T. M. Morgan, M. S. Anthony, R. M. Blair, J. D. Wagner, and T. B. Clarkson Effects of Soy Isoflavones and Conjugated Equine Estrogens on Inflammatory Markers in Atherosclerotic, Ovariectomized Monkeys J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1734 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vega-Lopez, K.-J. Yeum, J. L Lecker, L. M Ausman, E. J Johnson, S. Devaraj, I. Jialal, and A. H Lichtenstein Plasma antioxidant capacity in response to diets high in soy or animal protein with or without isoflavones Am. J. Clinical Nutrition, January 1, 2005; 81(1): 43 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kreijkamp-Kaspers, L. Kok, M. L Bots, D. E Grobbee, J. W Lampe, and Y. T van der Schouw Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women Am. J. Clinical Nutrition, January 1, 2005; 81(1): 189 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Greany, J. A. Nettleton, K. E. Wangen, W. Thomas, and M. S. Kurzer Probiotic Consumption Does Not Enhance the Cholesterol-Lowering Effect of Soy in Postmenopausal Women J. Nutr., December 1, 2004; 134(12): 3277 - 3283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-G. Zhuo, M. K. Melby, and S. Watanabe Soy Isoflavone Intake Lowers Serum LDL Cholesterol: A Meta-Analysis of 8 Randomized Controlled Trials in Humans J. Nutr., September 1, 2004; 134(9): 2395 - 2400. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
) represent endothelium-dependent vasodilatory responses. Nitroglycerin-mediated vasodilation (
) represents endothelium-independent responses. The effect of the nitroglycerin-by-treatment interaction was not significant (P = 0.31), with a significant main effect difference noted among treatments. PFV after treatment with isolated soy protein containing isoflavones (Soy+) was significantly (37%; P = 0.03) lower than that after treatment with total milk protein (TMP). PFV after treatment with ethanol-washed isolated soy protein with trace isoflavones (Soy-) was intermediate in value and did not differ significantly from that after TMP treatment. The nitroglycerin vasodilatory response was more robust than the postocclusion response. Significance (P < 0.05) was determined with the use of two-factor repeated-measures ANOVA with interaction term and the Tukey-Kramer post hoc test.